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Sensory afferent signaling is required for normal function of the lower urinary tract
(LUT). Despite the wide prevalence of bladder dysfunction and pelvic pain syndromes,
few effective treatment options are available. Serotonin receptor 5-HT3A is a known
mediator of visceral afferent signaling and has been implicated in bladder function.
However, basic expression patterns for this gene and others among developing bladder
sensory afferents that could be used to inform regenerative efforts aimed at treating
deficiencies in pelvic innervation are lacking. To gain greater insight into the molecular
characteristics of bladder sensory innervation, we conducted a thorough characterization
of Htr3a expression in developing and adult bladder-projecting lumbosacral dorsal root
ganglia (DRG) neurons. Using a transgenicHtr3a-EGFP reporter mouse line, we identified
5-HT3A expression at 10 days post coitus (dpc) in neural crest derivatives and in 12 dpc
lumbosacral DRG. Using immunohistochemical co-localization we observedHtr3a-EGFP
expression in developing lumbosacral DRG that partially coincides with neuropeptides
CGRP and Substance P and capsaicin receptor TRPV1. Amajority ofHtr3a-EGFP+DRG
neurons also express a marker of myelinated Aδ neurons, NF200. There was no
co-localization of 5-HT3A with the TRPV4 receptor. We employed retrograde tracing in
adult Htr3a-EGFPmice to quantify the contribution of 5-HT3A+ DRG neurons to bladder
afferent innervation. We found that 5-HT3A is expressed in a substantial proportion
of retrograde traced DRG neurons in both rostral (L1, L2) and caudal (L6, S1) axial
levels that supply bladder innervation. Most bladder-projecting Htr3a-EGFP+ neurons
that co-express CGRP, Substance P, or TRPV1 are found in L1, L2 DRG, whereas
Htr3a-EGFP+, NF200+ bladder-projecting neurons are from the L6, S1 axial levels.
Our findings contribute much needed information regarding the development of LUT
innervation and highlight the 5-HT3A serotonin receptor as a candidate for future studies
of neurally mediated bladder control.
Keywords: serotonin, neural crest, autonomic nervous system, lower urinary tract, dorsal root ganglia
Ritter and Southard-Smith Htr3a in Developing Dorsal Root Ganglia
INTRODUCTION
The lower urinary tract (LUT), comprised of the bladder
and urethra, relies on autonomic and sensory neural input
for storage and appropriate expulsion of urine from the
body. Damage to or degeneration of any neural component
of this system can lead to chronic pelvic pain or bladder
dysfunction, which can severely diminish patient quality of life.
Additionally, sensitization of sensory components that originate
within the dorsal root ganglia can occur in response to bladder
inflammation or chronic interstitial cystitis. Current treatment
options for these conditions tend to affect many diverse neuronal
populations and thus have numerous adverse side effects. Better
understanding of the molecular features of bladder-innervating
sensory afferents, and how they develop, has the potential to
inform more pharmacologically specific treatment options for
these conditions.
Afferent fibers supplying the LUT express a wide variety of
ion channels and neuropeptides with known roles in mediating
mechanosensation of bladder fullness and nociceptive processing
of painful stimuli (de Groat and Yoshimura, 2009). Many of these
markers, such as TRPV1 and TRPV4, have been well-studied.
Surprisingly, serotonin signaling has not been as thoroughly
investigated in the LUT, despite its known importance in sensory
processing in other systems. Serotonin receptors are expressed
in both the central and peripheral nervous systems and are
involved in every level of nociception, from the peripheral site
of injury or inflammation to cognitive perception of pain (Gold
and Gebhart, 2010). Serotonin can exert both pronociceptive and
antinociceptive effects, depending on the receptors activated in
peripheral tissues and in the spinal cord. Of the 14 different
serotonin receptor subtypes, 5-HT3A (encoded by the Htr3a
gene) is known to be an especially important mediator of
nociception (Zeitz et al., 2002; Kayser et al., 2007), including
visceral pain. Specifically, antagonizing 5-HT3A alleviates pain
associated with intestinal inflammation and irritable bowel
syndrome (Chen et al., 2009; Walstab et al., 2010; Machu,
2011). Additionally, normal 5-HT3A receptor activity is required
for adult LUT innervation and bladder function (Bhattacharya
et al., 2004). However, it remains unclear what sensory subtypes
normally express the 5-HT3A receptor and the extent to which
5-HT3A+ neurons contribute to normal bladder innervation.
Specification of the sensory neuronal lineage from neural crest
progenitors occurs between 9.5 and 11 days post coitus (dpc)
as neurogenesis progresses. Differentiation of DRG neurons
and acquisition of sensory subtype-specific markers has been
reported around 14.5 dpc (Marmigerè and Ernfors, 2007; Bachy
et al., 2011; Zou et al., 2012). Despite evidence that points to
an effect of 5-HT3A on bladder function (Espey et al., 1998;
Bhattacharya et al., 2004; Hall et al., 2015), no prior studies
have assessed the expression of this receptor in DRG during the
developmental stages when the LUT is being innervated. To date,
Htr3a gene expression in DRG has only been characterized via
in situ hybridization at a single developmental time point (Tecott
et al., 1993; Diez-Roux et al., 2011). Using a transgenic Htr3a-
EGFP mouse line in conjunction with immunohistochemistry
and retrograde tracing, we characterized the developmental
expression patterns of 5-HT3A in DRG and the contribution
of neurons expressing this receptor to adult urinary bladder
sensory innervation. We find that this serotonin receptor
exhibits dynamic expression patterns over the course of sensory




All experimental protocols were approved by the Vanderbilt
University Institutional Animal Care and Use Committee
(IACUC). Tg(Htr3a-EGFP)DH30Gsat/Mmnc (Stock Number
000273-UNC) transgenic mice were obtained from the Mutant
Mouse Resource & Research Center at the University of North
Carolina. Htr3a-EGFP mice were maintained as heterozygotes
on an outbred Swiss Webster background (Taconic). All animals
were provided food and water ad libitum and kept on a 14-h
on, 10-h off light cycle. To obtain tissues at specific fetal stages,
males and female mice were paired for overnight matings and the




Harvested mouse fetuses were collected into ice-cold 1X
Phosphate Buffered Saline (PBS). All fetuses and micro dissected
tissues were fixed in 10% Neutral Buffered Formalin (NBF, Sigma
Aldrich HT501128). Younger fetuses (10, 11, and 12 dpc) were
fixed intact for 6 h at 4◦C. Older fetuses, 14 and 18 dpc, were
further sub-dissected to allow permeation of fixative to visceral
tissues, then fixed overnight at 4◦C. Because the DRG in P2 pups
are small and fragile, “backbone blocks” were dissected from axial
levels T13 to S4 and fixed intact overnight at 4◦C. P14, P28, and
P90 DRG were sub-dissected and fixed for 3 h at 4◦C. Following
fixation, all tissues were washed in cold 1XPBS 3 times for 15 min
with a final 1 h wash. Tissues for cryo-sectioning were infiltrated
with 30% sucrose in 1XPBS and stored in the same solution at
4◦C until the day of embedding and sectioning.
Immunohistochemistry Staining
Tissues were embedded in Tissue Freezing Medium (TFM,
General Data, #TFM) and immediately sectioned in a Leica
Cryostat (CM1900-UV). Sagittal sections 20µm thick were
mounted onto slides treated with 3-APES (Sigma-Aldrich,
A3648). For the purpose of cell counting in adult DRGs, every
fifth section was mounted to ensure a minimum gap of 100µm
between sections to avoid double-counting cells. Sections on
slides were dried on a 37◦C slide warmer for 30min and
protected from light. Slides were then immersed in 1XPBS-0.3%
Triton-X100 for 5min at room temperature to remove TFM
and permeabilize the tissue for improved antibody penetration.
Blocking solution comprised of 1XPBS-0.3%TritonX-100, 10%
Bovine SerumAlbumin (Sigma-Aldrich, A2153), and 5%Normal
Donkey Serum (Jackson ImmunoResearch, 017-000-121, RRID
AB_2337258) was applied to sections for a minimum of 30 min
at room temperature. The same solution was used to dilute
Frontiers in Neuroscience | www.frontiersin.org 2 January 2017 | Volume 10 | Article 592
Ritter and Southard-Smith Htr3a in Developing Dorsal Root Ganglia
TABLE 1 | Primary Antibodies Used in Immunohistochemistry Experiments.
Antibody Host Vendor RRID Dilution Validation in Knockout Mouse Line
CGRP Rabbit Sigma Aldrich, #C8198 AB_259091 1:1000 Glaser et al., 2007
Substance P Rabbit ImmunoStar, #20064 AB_572266 1:500 Cao et al., 1998
TRPV1 Rabbit Neuromics, #RA14113 AB_2194034 1:500 Baiou et al., 2007
TRPV4 Rabbit Alomone Labs, #ACC-034 AB_2040264 1:1000 Gevaert et al., 2007
NF200 Rabbit Sigma Aldrich, #N4142 AB_477272 1:500 Cassereau et al., 2013
Hu Human Vanda Lennon, Mayo Clinic N/A 1:10,000 N/A
All primary antibodies used, except for Hu, have been validated in knockout mouse lines.
TABLE 2 | Secondary antibodies used in immunohistochemistry
experiments.











the primary and secondary antibodies. All antibodies used in
this study have been thoroughly characterized and validated
in knockout mouse lines, as summarized in Tables 1, 2 (Cao
et al., 1998; Baiou et al., 2007; Gevaert et al., 2007; Glaser et al.,
2007; Cassereau et al., 2013). Blocking solution was tipped off
the slides, and diluted primary antibody incubated on sections
overnight at 4◦C. On the following day, sections were rinsed
with sterile 1XPBS and incubated in secondary antibody for 1 h
at room temperature. After rinsing, 0.5mM cupric sulfate in
50mM ammonium acetate buffer (pH 5.0) was applied to tissue
sections for 10min to quench autofluorescence (Potter et al.,
2012). Finally, a gentle rinse with sterile water was used to stop
the CuSO4 quenching reaction. The slides were mounted and
coverslipped with AquaPolyMount (PolySciences, Inc., 18606),
and imaged using a Zeiss LSM 510Meta confocal microscope.
Retrograde Tracing of Bladder-Innervating
Neurons
Retrograde Tracing Surgery
Adult Htr3a-EGFP mice at 12 weeks of age were used for
retrograde tracing experiments. Male mice were used exclusively
to avoid confounding effects of estrous cycle on neuronal gene
expression patterns (Mónica Brauer and Smith, 2015). Injection
of retrograde tracing dye, Fast Blue, into the bladder dome was
carried out under general anesthesia as previously described
(Payne et al., 2015). Briefly, mice were fully anesthetized via
4% isoflurane inhalation and kept on a heating pad for the
duration of the surgery. An abdominal incision through the skin
and muscle was made to reveal the bladder, which was then
gently exteriorized and moistened with sterile saline solution.
Fast Blue retrograde tracing dye (PolySciences, Inc., 17740-1) was
injected in 9 different locations in 0.5µL volumes: three sites near
the bladder neck, three sites around the middle circumference
of the bladder, and three sites near the apex of the bladder
dome. A Hamilton syringe equipped with a 33G needle was used
for dye injections to avoid bleeding and bladder tissue damage
(Hamilton Company #7803-05). Sterile cotton swabs and surgical
grade sterile saline were used to carefully remove any excess
dye leaking from each injection site. To avoid any dye leakage
from the injection sites, sterile cotton swabs and surgical grade
sterile saline were used to carefully blot and wash away any
excess dye. The bladder was then returned to the abdominal
cavity, and the muscle and skin were subsequently sutured. Mice
were treated with pre-operative and post-operative analgesic for
pain management (buprenex, 0.1 mg/kg, Patterson Veterinary
Supply 12496075705). To permit transport of dye back to the
neuron somata in the DRG, mice were euthanized on the 7th
day following dye tracer injection. Dorsal root ganglia were
sub-dissected and processed as described above.
Cell Counting
Images were captured via confocal microscopy using anOlympus
FV-1000 inverted confocal microscope. Images were then
exported from the FluoView viewing software as.tiff files and
assembled in Adobe Photoshop (2014 2.2 release, Adobe Systems
Inc.). Due to heterogeneity in expression intensity of the Htr3a-
EGFP transgene, images were minimally adjusted for optimal
brightness and contrast. Numbers of neurons (Hu+ cells),Htr3a-
EGFP+ cells, Fast Blue+ cells, and cells labeled with markers of
sensory neurons were manually quantified by visual inspection
of assembled confocal stacks. Proportions of neuronal subtypes
were calculated as the number of immuno-positive cells for each
marker over the total number of Hu+ neurons for each section.
Cells were counted from three to six sections of three DRG from
each axial level group from four Htr3a-EGFP animals.
Data Analysis
One-way ANOVA was conducted to examine differences in
average Htr3a-EGFP and Fast Blue proportions between all axial
levels examined (L1,L2; L3-L5; L6,S1). Differences in Htr3a-
EGFP and Fast Blue proportions between specific axial level
groups were analyzed by Welch’s t-test. P-values were corrected
for multiple comparisons; p-values less than 0.05 were considered
to be statistically significant. Proportions of neuronal subtype
markers between lumbar and sacral axial levels were analyzed
by Welch’s t-test; p-values less than 0.05 were considered to be
statistically significant.
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RESULTS
Htr3a-EGFP Is Expressed Early in Sensory
Nervous System Development
We first sought to define the time point at which Htr3a
expression initiates during early phases of DRG neurogenesis.
To visualize Htr3a gene expression, we employed the Tg (Htr3a-
EGFP) DH30Gsat BAC transgenic reporter mouse line, hereafter
referred to as Htr3a-EGFP. Validation of this reporter line as
an accurate readout of endogenous gene expression has been
performed by other groups (Gong et al., 2003; Vucurovic et al.,
2010). Using Htr3a-EGFP transgenic tissues, the earliest stage
at which we observed transgene expression by whole mount
imaging was 10 dpc, where strong EGFP fluorescence was
evident in the neural crest derived cranial ganglia and within
the neural tube (Figure 1A). Hu C/D, a pan-neuronal marker,
was strongly expressed in DRG of 11 dpc fetuses along their
entire length; however, Htr3a-EGFP expression in the DRG
was restricted to cervical and upper thoracic axial levels at
this stage (data not shown). We first observed Htr3a-EGFP
transgene expression in lumbosacral DRG that are known to
provide bladder innervation at 12 pdc (Figures 1B,C). At this
stage Htr3a-EGFP expression was observed in a rostral to
caudal gradient among maturing DRG (Figures 1B,C) within
a subset of Hu+ differentiated neurons (Figures 1D–D”). The
rostral vs. caudal difference in Htr3a-EGFP expression intensity
was prominent, with many neurons exhibiting Htr3a-EGFP in
one lumbosacral DRG while few cells express the transgene
in an immediately adjacent lumbosacral DRG. Additionally,
at 12 dpc neuronal processes extending from lumbosacral
DRG toward the urogenital sinus and pelvic region are visibly
labeled by EGFP (Figure 1C). These experiments show that
the 5-HT3A receptor is expressed early in neural crest-derived
(Hu+) neurons and is first expressed in lumbosacral DRG by
12 dpc.
Htr3a-EGFP Co-localizes with
Neuropeptides CGRP and Substance P in a
Subset of DRG Neurons
Calcitonin Gene Related Peptide (CGRP) and Substance P
(SP) have well-established roles in modulating adult LUT
function and pain processing (Laird et al., 2000; Saban et al.,
2000; Kiss et al., 2001; Lagerström et al., 2011; Russell
et al., 2014) and are normally produced by unmyelinated Aδ
nociceptive neurons (Arms and Vizzard, 2011). However, the
expression patterns of these neuropeptides in developing mouse
lumbosacral DRG projecting to the bladder are unknown. Using
immunohistochemistry on Htr3a-EGFP+ transgenic tissues,
we sought to define co-expression patterns of nociceptive
neuropeptides and Htr3a in developing lumbosacral DRG.
At stage 14 dpc, Htr3a-EGFP was strongly expressed in
the majority of lumbosacral DRG neurons; however, CGRP
expression was negligible at this stage (Figures 2A–A”). By 18
dpc, CGRP was clearly present with a continuous gradient
of expression intensity that ranged from moderate to strong
between individual cells. Immunostaining for CGRP was
observed to co-localize with Htr3a-EGFP fluorescence in
a subset of large-diameter neurons (Figures 2B–B”). We
observed that Htr3a-EGFP transgene expression gradually
becomes restricted to a subset of cells during the course
of postnatal development. This restriction became notable
as early as postnatal day (P)2 and was also prevalent at
P14 and P28. Specifically, as DRG development progressed,
the number of neurons expressing Htr3a-EGFP diminished.
Among the neurons that remained Htr3a-EGFP+, there was
considerable heterogeneity in expression intensity, with some
cells exhibiting bright EGFP fluorescence while others are
substantially dimmer. Despite the gradual restriction of Htr3a-
EGFP expression and the heterogeneity in expression intensity
between individual neurons, partial co-localization with CGRP
was maintained through postnatal development and into
adulthood (Figures 2C–E”).
While CGRP and SP are often co-expressed in afferent
neurons, other evidence suggests that these neuropeptides do
not always overlap and have functionally distinct roles in
nociception (Su et al., 1986; Kestell et al., 2015). Given this
information we examined co-expression patterns of SP and
Htr3a-EGFP. Upon staining for SP, we noted faint and diffuse
expression throughout the ganglion and partial overlap with
Htr3a-EGFP transgene fluorescence at 14 dpc (Figures 3A–A”).
Co-localization by immunohistochemical staining of 18 dpc
DRG for SP revealed that the majority of SP+ neurons
also expressed Htr3a-EGFP (Figures 3B–B”). However, shortly
after birth at P2, co-localization of Htr3a-EGFP and SP
lessened as Htr3a-EGFP developed a heterogeneous pattern
of expression intensity among individual neurons within the
ganglion (Figures 3C–C”). Substance P staining in postnatal
DRG was more uniform; all SP+ neurons exhibited a
similar level of expression intensity. At 2 and 4 weeks after
birth, only a subset of DRG neurons co-expressed Htr3a-
EGFP and SP (Figures 3D–E”). From these experiments we
conclude that fetal lumbosacral DRG neurons widely co-
express 5-HT3A and the neuropeptides CGRP and Substance
P, and as postnatal maturation of the DRG occurs, expression
of these markers becomes refined to a subpopulation of
neurons.
The Majority of TRPV1+ Neurons
Co-express Htr3a-EGFP
Transient Receptor Potential (TRP) channels are necessary for
normal adult bladder function (Birder et al., 2002; Arms and
Vizzard, 2011; Yoshiyama et al., 2015). Despite the known
physiological interaction of 5-HT3A and TRPV1 receptors in
other sensory ganglia (Loyd et al., 2011; Kim et al., 2014), the
co-localization of TRPV1 with Htr3a has not previously been
examined during development. To address this gap in knowledge
we conducted immunostaining on Htr3a-EGFP lumbosacral
DRG for TRPV1. At 14 dpc we found diffuse, very low expression
of the TRPV1 receptor (Figures 4A–A”). By 18 dpc, TRPV1
expression was weak and diffuse throughout the ganglion, with
only a few cells exhibiting strong expression. Of the TRPV1+
cells at 18 dpc, nearly all of them co-express Htr3a-EGFP
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FIGURE 1 | Htr3a is expressed early in fetal development of sensory neurons. (A) Lateral whole-mount image of an Htr3a-EGFP transgenic fetus age 10 days
post coitus (dpc). EGFP fluorescence is visible in the cranial ganglia (V, VII/VIII, IX, X) and neural tube (nt). (B) Lateral Whole-mount view of an Htr3a-EGFP 12 dpc
mouse fetus at the trunk axial level between the forelimbs and hindlimbs. Htr3a-EGFP transgene expression is evident in the dorsal root ganglia (DRG) and pancreas
(p). (C) Sagittal cryo-section of Htr3a-EGFP 12 dpc fetus, stained with Hu to label all neurons (blue). EGFP expression is observed in the lumbosacral DRG. (D–D”)
200x magnification of two sacral DRG seen in (C). Counter-staining with Hu C/D allows comparison of EGFP fluorescence to the total neuronal population.
(Figures 4B–B”). TRPV1 expression increased in a subset of
neurons by P2 at the same time that Htr3a-EGFP became
less widespread and began to show heterogeneous levels of
EGFP fluorescence among individual neurons (Figures 4C–C”).
Heterogeneous expression of the Htr3a-EGFP transgene and
partial co-localization with TRPV1 was consistently observed
at P14 and P28 (Figures 4D–E”). From these experiments
we conclude that as DRG neuronal populations mature,
there is substantial overlap of Htr3a and TRPV1 expression,
but lumbosacral DRG also exhibit many Htr3a+;TRPV1-
neurons.
Htr3a-EGFP Does Not Co-localize with
TRPV4
Despite the known importance of TRPV4 in visceral nociception
and adult bladder function (Cenac et al., 2008; Christianson et al.,
2009; Everaerts et al., 2010; Franken et al., 2014; Yoshiyama et al.,
2015), developmental expression patterns of this nociceptive
marker in DRG have not previously been examined. To
determine co-localization patterns of Htr3a-EGFP and TRPV4,
we stained transgenic tissues for TRPV4. While we did observe
positive staining in other known TRPV4+ tissues (kidney, bone,
brain; data not shown), we did not detect TRPV4 in fetal or
neonatal lumbosacral DRG (Figures 5A–C”). TRPV4 expression
was detected in a subset of P14 and P28 DRG neurons; however,
we did not observe overlap of TRPV4 immuno-staining with
Htr3a-EGFP transgene expression at any of the stages examined
(Figures 5D–E”).
Htr3a-EGFP Is Expressed in a Subset of
Myelinated Sensory Neurons
Following our characterization of Htr3a-EGFP in nociceptive
C-fiber neurons, we next wanted to define patterns of overlap
with mechanosensitive Aδ nociceptors. To this end we conducted
immunohistochemical staining for Neurofilament 200 (NF200),
a known marker of myelinated Aδ sensory neurons (Lawson
et al., 1993). While expression of Htr3a-EGFP was prominent
in the majority of cells in 14 dpc DRGs, NF200 was dim
in a subset of cells and rarely overlapped with Htr3a-EGFP
(Figures 6A–A”). By 18 dpc, however, many neurons expressed
NF200 and some of these NF200+ cells also co-expressed Htr3a-
EGFP (Figures 6B–B”). At P2, widespread co-expression of
Htr3a-EGFP andNF200 occurred and wasmaintained at P14 and
P28 (Figures 6C–E”).
Htr3a-EGFP Is Expressed in the Majority of
Bladder-Innervating Afferent Neurons
Given the known significance of 5-HT3A signaling in visceral
nociception and neural control of bladder function (Zeitz et al.,
2002; Bhattacharya et al., 2004; Faerber et al., 2007; Hall et al.,
2015), we next sought to determine the proportion of 5-HT3A+
DRG neurons that contribute to bladder sensory innervation
in adult mice. To do this, we conducted retrograde tracing of
bladder innervation in adult male transgenic mice by injecting
Fast Blue (FB) dye into the detrusor and quantified proportions
of Htr3a-EGFP+ neurons whose soma were labeled with FB
(Table 3 and Figure 7D). Among all three of the axial level
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FIGURE 2 | Htr3a-EGFP and Calcitonin Gene Related Peptide (CGRP) are co-expressed in a subset of neurons through development and adulthood.
Confocal images of cryosections from Htr3a-EGFP transgenic animals stained with anti-CGRP are shown. All DRG presented are from lumbosacral axial levels. (A–A”)
Sagittal section of 14 dpc fetal DRG. (B–B”) Sagittal section of 18 dpc fetal DRG. (C–C”) Coronal section of P2 DRG. (D–D”) Cryosection of P14 male DRG. (E–E”)
Cryosection of P28 male DRG. All zoom insets are 400X.
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FIGURE 3 | Some, but not all, Htr3a-EGFP neurons express Substance P neuropeptide. Confocal images of cryosections from Htr3a-EGFP transgenic animals
stained with anti-Substance P are shown. All DRG presented are from lumbosacral axial levels. (A–A”) Sagittal section of 14 dpc fetal DRG. (B–B”) Sagittal section of
18 dpc fetal DRG. (C–C”) Coronal section of P2 DRG. (D–D”) Cryosection of P14 male DRG. (E–E”) Cryosection of P28 male DRG. All zoom insets are 400X.
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FIGURE 4 | The majority of adult TRPV1+ neurons also express Htr3a-EGFP. Confocal images of cryosections from Htr3a-EGFP transgenic animals stained
with anti-TRPV1 are shown. All DRG presented are from lumbosacral axial levels. (A–A”) Sagittal section of 14 dpc fetal DRG. (B–B”) Sagittal section of 18 dpc fetal
DRG. (C–C”) Coronal section of P2 DRG. (D–D”) Cryosection of P14 male DRG. (E–E”) Cryosection of P28 male DRG. All zoom insets are 400X.
Frontiers in Neuroscience | www.frontiersin.org 8 January 2017 | Volume 10 | Article 592
Ritter and Southard-Smith Htr3a in Developing Dorsal Root Ganglia
FIGURE 5 | Htr3a-EGFP does not co-localize with TRPV4 in lumbosacral DRG. Confocal images of cryosections from Htr3a-EGFP transgenic animals stained
with anti-TRPV4 are shown. All DRG presented are from lumbosacral axial levels. (A–A”) Sagittal section of 14 dpc fetal DRG. (B–B”) Sagittal section of 18 dpc fetal
DRG. (C–C”) Coronal section of P2 DRG. (D–D”) Cryosection of P14 male DRG. (E–E”) Cryosection of P28 male DRG. All zoom insets are 400X.
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FIGURE 6 | A subset of Htr3a-EGFP neurons express Neurofilament 200. Confocal images of cryosections from Htr3a-EGFP transgenic animals stained with
anti-NF200 are shown. All DRG presented are from lumbosacral axial levels. (A–A”) Sagittal section of 14 dpc fetal DRG. (B–B”) Sagittal section of 18 dpc fetal DRG.
(C–C”) Coronal section of P2 DRG. (D–D”) Cryosection of P14 male DRG. (E–E”) Cryosection of P28 male DRG. All zoom insets are 400X.
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TABLE 3 | Proportions of Total Neurons (Hu+) Expressing Htr3a-EGFP and
Projecting to the Bladder (Fast Blue+).
L1, L2 L3-L5 L6, S1
Htr3a-EGFP+/Hu+ 24.89 ± 0.56% 20.68 ± 0.38% 23.97 ± 0.85%
Fast Blue+/Hu+ 2.97 ± 0.14% 0.063 ± 0.025% 11.99 ± 0.30%
EGFP+, FB+/Hu+ 1.92 ± 0.10% 0.027 ± 0.0099% 5.10 ± 0.28%
Total Hu+ Neurons
Counted 47,208 57,073 40,415
groups, we noted significant differences in proportions of Htr3a-
EGFP+ and FB+ neurons (p = 1.5564e-6 and p = 8.8e-16,
respectively). At lumbar axial levels (L1, L2), nearly 25% of
all Hu+ neurons express Htr3a-EGFP (Figures 7A–A”). Sacral
axial level DRG neurons (L6, S1) are known to supply the
majority of bladder sensory innervation, and we observed a
similar proportion of Htr3a-EGFP expression in this population
(23.9% of total L6, S1 Hu+ neurons expressed Htr3a-EGFP;
Figures 7C–C”). Significantly fewer numbers of neurons within
L3-L5 axial level DRGs, which do not contribute to bladder
sensory innervation, showedHtr3a-EGFP+ expression (20.7% of
Hu+ neurons were Htr3a-EGFP+, p = 7.168e-9 compared to
L1, L2 and p = 0.002092 compared to L6, S1; Figures 7B–B”).
When we quantified total numbers of neurons labeled by Fast
Blue (FB+) retrograde tracing, we observed that nearly 3% of
L1, L2 total neurons (Hu+) innervate the detrusor. In contrast,
nearly 12% of L6, S1 neurons, a four-fold increase relative to
lumbar levels, were labeled by Fast Blue in our experiments (p
= 8.8e-16). We only very rarely observed any FB+ neurons in
L3-L5 DRGs (0.067% of all Hu+ L3-L5 neurons; 26 out of 57,073
cells). The proportions of retrograde traced neurons in each of
these axial levels are consistent with prior percentages reported
for adult mice by other research groups (Keast and De Groat,
1992; Brumovsky et al., 2012).
Given that we had observed co-localization of Htr3a
expression with markers of multiple types of nociceptive sensory
neurons during development of lumbosacral DRG, we next
sought to determine whether these subclasses of bladder-
innervating neurons in adult mice maintain expression of the
5-HT3A receptor. To do this, we stained DRG sections from
adult Htr3a-EGFP mice that had been processed for Fast Blue
retrograde labeling of bladder projections for CGRP, Substance
P, TRPV1, and NF200 (Figure 8 and Table 4). Of all bladder-
innervating neurons at the L1, L2 axial levels (that is, all Fast
Blue+ neurons), the majority of them express Htr3a-EGFP
(62.8%). In more caudal DRG (L6, S1), where the majority of
bladder sensory innervation originates, 40.3% of Fast Blue+DRG
neurons express Htr3a-EGFP. The difference in proportions of
Htr3a-EGFP+, FB+ neurons in the lumbar and sacral axial
levels was statistically significant (p= 4.349e-15). CGRP staining
was observed in approximately half of all FB+ L1, L2 neurons
(52.0%), while 36.9% of FB+ L6, S1 neurons were CGRP+ (p =
0.00292). In L1, L2 DRGs, 36.7% of FB+ neurons co-expressed
Htr3a-EGFP and CGRP, but this proportion was reduced by half
in L6, S1 neurons (19.6%) (p = 0.000162). When we stained
for Substance P, we found similar expression levels in FB+
neurons in L1, L2 and L6, S1 DRG (42.8 vs. 37.7%, p = 0.251).
However, we did observe a significant difference in proportions
of FB+ neurons co-expressing Htr3a-EGFP and Substance P
(32.4% of L1, L2 and 17.3% of L6, S1 FB+ neurons, p =
0.000310). Unlike the markers for peptidergic neurons, TRPV1
staining was nearly equivalent in FB+ neurons for both axial
level groups; 19.7% of L1, L2 neurons were FB+ and 20.7% of
L6, S1 neurons were labeled by Fast Blue (p = 0.8332). Despite
the fact that proportions of TRPV1+ neurons were comparable
in both lumbar and sacral bladder innervating DRG, there was
a 2-fold difference in the numbers of Htr3a-EGFP+, TRPV1+
neurons in these locations. While 13.9% of TRPV1+ L1, L2
neurons exhibited co-expression of Htr3a-EGFP, only 7.4% of
neurons were Htr3a-EGFP+, TRPV1+ among L6, S1 neurons.
However, this difference did not reach statistical significance (p
= 0.0741). Proportions of FB+ neurons that stained for NF200
were strikingly different from the other markers we examined.
We found that 32.4% of FB+ L1, L2 neurons are NF200+, but
this population was doubled in L6, S1 axial levels (66.6%) (p =
1.94e-8). NF200 and Htr3a-EGFP co-localize in 16.5% of FB+
L1, L2 neurons and in 36.3% of FB+ L6, S1 neurons (p =
7.544e-7). From these experiments we conclude that there are
significant differences in the proportions of sensory neuron types
that express the 5-HT3A receptor among the DRG groups that
contribute to bladder innervation.
The emerging expression patterns and intensity of expression
for each of the markers we examined relative to Htr3a are
graphically summarized in Figure 9.
DISCUSSION
Serotonin (5-hydroxytryptamine, 5-HT) is a known mediator
of nociception, but contradictory effects are observed due to
the wide variety of serotonin receptor subtypes expressed by
nociceptors and their target tissues. One such receptor, 5-HT3A
(encoded by Htr3a in mice), is a ligand-gated ion channel
with previously established roles in potentiating pain (Zeitz
et al., 2002; Hall et al., 2015). Despite its known expression
in fetal neural crest derivatives (Tecott et al., 1993, 1995),
comprehensive temporal profiling of 5-HT3A in developing
sensory neuron populations has not been pursued. In this study
we used the Htr3a-EGFP transgenic reporter line as a surrogate
in combination with immunohistochemical labeling to identify
neuron populations expressing 5-HT3A relative to a variety
of nociceptive markers in normal fetal and postnatal DRG
development.
We first noted expression of the Htr3a-EGFP transgene at
10 dpc in the neural tube and cranial ganglia, followed by
up-regulation in lumbosacral DRG by 12 dpc. The early and
sustained expression in sensory lineages suggests a functional
role for 5-HT3A in differentiation of sensory neurons; however,
the specific effects of this receptor in sensory neurogenesis and
maturation remains to be determined.
Given that 5-HT3A is known to be involved in nociceptive
processing (Zeitz et al., 2002), especially in visceral pain and
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FIGURE 7 | L1, L2 and L6, S1 axial levels harbor bladder-projecting neurons. Images of lumbosacral DRG harvested from Htr3a-EGFP transgenic male mice
after retrograde tracing of bladder-projecting neurons are shown. (A–A”) L1, L2 axial level DRG sections. (B–B”) L3-L5 axial level DRG sections. (C–C”) L6, S1 axial
level dorsal root ganglia sections. (D) Average percentages of Hu+ DRG neurons expressing the Htr3a-EGFP transgene, labeling with Fast Blue, and co-labeling with
Htr3a-EGFP and Fast Blue at axial level groups L1, L2; L3-L5; and L6, S1. Error bars are standard error of the mean, n = 4 animals, 3–5 sections from 3 DRG
quantified from each animal. ***p < 0.005, ****p < 0.001. Differences that are not significant (n.s.) are also indicated.
inflammation (Randich et al., 2008; Kato, 2013), we sought
to define the complement of nociceptive neuron subtypes that
express the 5-HT3A receptor in development. Neuropeptides
CGRP and Substance P are known effectors of inflammation
and nociceptive processing (Laird et al., 2000; Saban et al.,
2000; Kiss et al., 2001; Lagerström et al., 2011; Russell et al.,
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FIGURE 8 | Distinct expression patterns of 5-HT3A receptor in subclasses of bladder-projecting afferents. Average percentages of bladder-projecting (Fast
Blue+) neurons expressing the Htr3a-EGFP transgene and markers of sensory neuron subtypes in L1, L2 and L6, S1 DRG. Gray coloring represents L1, L2
proportions and black coloring represents L6, S1 proportions. Htr3a-EGFP average proportions in L1, L2 and L6, S1 DRG are the leftmost solid bars. Markers of
sensory neuron subtypes CGRP, Substance P, TRPV1, NF200 (solid bars) and co-expression of Htr3a-EGFP and subtype markers (striped bars) are grouped by the
marker used. Error bars are standard error of the mean, n = 4 animals, 3–5 sections from 3 DRG quantified from each animal. ***p < 0.005, ****p < 0.001. Differences
that are not significant (n.s.) are also indicated.
TABLE 4 | Proportions of Bladder-Projecting (Fast Blue+) Neuronal Subtypes in Lumbar (L1, L2) and Sacral (L6, S1) Axial Levels.
Average Proportion Marker+ out of Total Average Proportion Marker + out of Total
in L1, L2 FB+ Neurons Counted in L6, S1 FB+ Neurons Counted
Htr3a-EGFP+/FB+ 62.75 ± 0.02% 938 out of 1431 40.29 ± 0.015% 1967 out of 4691
CGRP+/FB+ 52.03 ± 4.46% 284 out of 463 36.96 ± 1.95% 494 out of 1340
EGFP+, CGRP+/FB+ 36.73 ± 3.97% 198 out of 463 19.62 ± 1.51% 267 out of 1340
Subs P+/FB+ 42.82 ± 3.96% 166 out of 387 37.66 ± 2.05% 464 out of 1240
EGFP+, Subs P+/FB+ 32.34 ± 3.56% 124 out of 387 17.29 ± 1.75% 236 out of 1240
TRPV1+/FB+ 19.74 ± 3.90% 56 out of 333 20.71 ± 2.45% 215 out of 1046
EGFP+, TRPV1+/FB+ 13.99 ± 3.34% 40 out of 333 7.38 ± 1.42% 90 out of 1046
NF200+/FB+ 32.42 ± 4.23% 90 out of 248 66.62 ± 3.19% 682 out of 1065
EGFP+, NF200+/FB+ 16.49 ± 2.55% 51 out of 248 36.32 ± 2.54% 367 out of 1065
Proportions of each marker or combination of markers were calculated for each DRG section and were then averaged. Averages are listed as percentages of total Fast Blue+ neurons
plus or minus the standard error of the mean. Total numbers of neurons counted for each marker or combination of markers, out of all Fast Blue+ neurons counted, for all sections, is
listed for L1, L2 and L6, S1 axial levels.
2014), but surprisingly their temporospatial expression patterns
in development have not previously been reported. We found at
14 dpc both of these neuropeptides are detectable at low levels
by immunohistochemistry in lumbosacral DRGs, while Htr3a-
EGFP expression is much more widespread among neurons
and is robustly transcribed. By 18 dpc, CGRP and Substance
P expression is stronger and largely co-localizes with Htr3a-
EGFP. In postnatal stages we noted the acquisition of a
heterogeneous pattern of Htr3a-EGFP transgene expression, in
which some neurons very strongly express Htr3a-EGFP while
others show moderate or dim levels. Despite these changes
in transgene expression, CGRP and Substance P expression
patterns remained consistent from 18 dpc through P2, P14, and
P28. Previous studies reported 5-HT3A receptor expression in
“nonpeptidergic” sensory neurons based on relatively infrequent
(4%) co-localization of 5-HT3A+ neurons identified by in
situ hybridization with SP+ neurons that were detected by
immunohistochemistry (Zeitz et al., 2002). In contrast, we
found that the majority of SP+ neurons in developing and
adult DRG expressed the Htr3a-EGFP transgene, indicating that
at least some 5-HT3A+ populations are in fact peptidergic.
The difference between our findings and prior reports maybe
due to stages examined, DRG axial levels evaluated, greater
ease of detecting EGFP fluorescence transgene vs. in situ
hybridization signal, or differences between the mouse strains
assayed.
TRP channels, namely TRPV1 and TRPV4, are key mediators
of multimodal nociceptive processing in the lower urinary
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tract (Birder et al., 2002; Arms and Vizzard, 2011; Yoshiyama
et al., 2015). Prior developmental studies of TRPV1 expression
utilizing RT-PCR identified dynamic expression levels of this
receptor over time, with low levels at 14 dpc (Hjerling-
Leﬄer et al., 2007). While this finding could have been
attributable to high expression in a few neurons with increasing
numbers of neurons expressing the receptor over time, our
immunohistochemical data shows that, in fact, TRPV1 is widely
expressed at low levels through the DRG at 14 dpc. As
lumbosacral DRG develop and mature, TRPV1 is expressed
at higher levels in a relatively small proportion of total DRG
neurons compared to Htr3a. The intensity of TRPV1 protein
staining continues to increase and stabilizes by P2, with partial
co-localization with Htr3a-EGFP in some DRG neurons. In
marked contrast, TRPV4 protein is not detected until P14 and
very rarely overlaps with Htr3a-EGFP transgene expression.
This finding is especially interesting given that TRPV1 and
TRPV4 have been implicated together in bladder afferent
signaling (Janssen et al., 2016). The significant proportion of
neurons co-expressing Htr3a-EGFP and NF200 indicates that
5-HT3A is not unique to a single nociceptive population,
but is present in neurons of diverse sensory modalities and
functions.
The second aim of our study was to determine the
neurochemical diversity of 5-HT3A+ neurons that contribute
to bladder sensory innervation. To this end we conducted
retrograde tracing with Fast Blue dye in adult Htr3a-EGFP
male mice and quantified proportions of 5-HT3A+ sensory
neuronal subtypes projecting to the bladder. Co-staining DRG
sections with nociceptive markers CGRP, SP, TRPV1, and
NF200 revealed differences in proportions of Htr3a+ subtypes
in lumbar (L1, L2) and sacral (L6, S1) groups of bladder-
innervating DRG. The majority of Fast Blue+ lumbar neurons
expressed Htr3a-EGFP, while less than half of the FB+ sacral
neurons were EGFP+. This difference in expression may have
a functional consequence; the majority of bladder muscle
innervation is derived from the sacral DRG group (L6, S1) and
these afferents are primarily stretch-sensitive mechanoreceptors
expressing NF200 (Xu and Gebhart, 2008). This finding is
especially interesting in the context of research conducted by
other groups. In guinea pig ex vivo bladder preparations, direct
application of serotonin resulted in significant excitation of
stretch-sensitive bladder muscle afferents (Zagorodnyuk et al.,
2009). Given the high proportion of sacral bladder afferents
co-expressing Htr3a and NF200, these excitatory effects may
be due to activation of this serotonin receptor. Future studies
could determine if L6, S1 bladder afferents co-expressing Htr3a
and NF200 also function to detect stretch of the bladder
detrusor.
Given the large proportion of bladder-innervating neurons
expressingHtr3a in male mice, 5-HT3A likely plays an important
role in bladder afferent neural activity. In our retrograde
tracing studies we focused only on male mice to avoid
estrous cycles as a confounding factor in gene expression
(Mónica Brauer and Smith, 2015). Since neurogenic bladder
and bladder pain syndromes occur more frequently and with
greater severity in women than men, sex-specific variation in
FIGURE 9 | Summary of developmental expression patterns in
lumbosacral Htr3a-EGFP+ dorsal root ganglia neurons. At 14 and 18
dpc, Htr3a-EGFP fluorescence is uniformly intense in the majority of
lumbosacral DRG neurons. Fluorescence intensity diversifies at postnatal day
2, with some cells still strongly expressing the transgene while others are
moderate or dim. This pattern is maintained through postnatal development
and adulthood. Neuropeptides CGRP and Substance P are both extremely
weak and diffuse at 14 dpc but their expression level increases by 18 dpc. The
expression patterns observed for these markers at 18 dpc is maintained
through adulthood. TRPV1 expression is negligible at fetal stages but
escalates after birth at P2 and maintains expression levels. TRPV4 is not
detected until P2 but is maintained from that time point to adulthood. NF200,
unlike the other markers, is expressed strongly in the majority of neurons at 14
dpc, and its expression levels are stable through all time points examined.
gene expression may be a contributing factor to these differences
(Irwin et al., 2006; Chrysanthopoulou and Doumouchtsis,
2014; Mónica Brauer and Smith, 2015). It will be of interest
in subsequent studies to investigate sex differences in Htr3a
gene expression patterns throughout development or into
adulthood.
The substantial proportions of bladder-innervating afferents
expressing 5-HT3A we identified were not unexpected,
given prior reports examining the role of this receptor in
micturition. Pharmacological activation of 5-HT3A at spinal and
supraspinal terminals resulted in inhibited sensory processing
and a decreased micturition threshold volume (Espey et al.,
1998). Complementary experiments showed that intrathecal
administration of a 5-HT3A antagonist led to bladder nociceptive
hypersensitivity (Hall et al., 2015), further supporting a critical
role for 5-HT3A in sensory mediation of bladder filling and
voiding. Future studies will need to focus on elucidating
the specific functional impact of this receptor on bladder
contractility and the consequences of its absence during nervous
system development.
Overall our work is the first to delineate the expression
patterns of a well-studied serotonin receptor in the understudied
system of bladder innervation in the context of sensory neuron
development. The work presented here serves as a foundation
for future studies focusing on the contribution of the 5-HT3A
receptor to common disorders such as chronic pelvic pain and
urinary incontinence.
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